Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04822298




Registration number
NCT04822298
Ethics application status
Date submitted
26/03/2021
Date registered
30/03/2021
Date last updated
20/12/2023

Titles & IDs
Public title
Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
Scientific title
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer
Secondary ID [1] 0 0
20180273
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer 0 0
NSCLC 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AMG 160

Experimental: Part 1: Dose Exploration - The dose exploration part of the study will estimate the MTD and/or the RP2D.

Experimental: Part 2: Dose Expansion - Cohort 1 Non-squamous NSCLC - Participants with non-squamous non-small cell lung cancer (NSCLC) will be administered the RP2D identified from the dose exploration part of the study.

Experimental: Part 2: Dose Expansion - Cohort 2 Squamous NSCLC - Participants with squamous NSCLC will be administered the RP2D identified from the dose exploration part of the study.


Treatment: Drugs: AMG 160
AMG 160 administered as an intravenous (IV) infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants who Experience One or More Dose-limiting Toxicities (DLTs)
Timepoint [1] 0 0
28 days
Primary outcome [2] 0 0
Number of Participants who Experience One or More Treatment-emergent Adverse Event (TEAE)
Timepoint [2] 0 0
Up to 3 years
Primary outcome [3] 0 0
Number of Participants who Experience One or More Treatment-related Adverse Events
Timepoint [3] 0 0
Up to 3 years
Primary outcome [4] 0 0
Number of Participants who Experience Clinically Significant Changes in Vital Signs
Timepoint [4] 0 0
Up to 3 years
Primary outcome [5] 0 0
Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [5] 0 0
Up to 3 years
Secondary outcome [1] 0 0
Objective Response (OR) per Modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Timepoint [1] 0 0
Up to 3 years
Secondary outcome [2] 0 0
Overall Survival
Timepoint [2] 0 0
Up to 3 years
Secondary outcome [3] 0 0
Progression-free Survival (PFS)
Timepoint [3] 0 0
Up to 3 years
Secondary outcome [4] 0 0
Time to Response
Timepoint [4] 0 0
Up to 3 years
Secondary outcome [5] 0 0
Time to Progression
Timepoint [5] 0 0
Up to 3 years
Secondary outcome [6] 0 0
Duration of Response
Timepoint [6] 0 0
Up to 3 years
Secondary outcome [7] 0 0
Time to Subsequent Therapy
Timepoint [7] 0 0
Up to 3 years

Eligibility
Key inclusion criteria
- Participant has provided informed consent prior to initiation of any study specific
activities/procedures.

- Histologically or cytologically confirmed stage 4 or recurrent non-squamous NSCLC
(Part 1); histologically or cytologically. confirmed stage 4 or recurrent NSCLC (Part
2 only, squamous cell histology/cytology allowed in Part 2).

- Without a driver mutation: disease progression following at least one line of prior
chemotherapy and at least 1 prior anti-programmed cell death protein 1
(PD1)/programmed death-ligand 1 (PDL1) therapy.

- With a driver mutation must experience disease progression on at least 1 targeted
therapeutic agent to be eligible.

- Detectable prostate-specific membrane antigen (PSMA) expression by PSMA positron
emission tomography (PET)/computed tomography (CT) imaging.

- Measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST)
1.1 criteria.

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 2.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Radiographic evidence of intratumor cavitation, major blood vessel invasion or
encasement by cancer.

- Untreated or symptomatic brain metastases and leptomeningeal disease.

- History of hemoptysis within 3 months prior to first dose.

- History or evidence of gastrointestinal inflammatory bowel disease (ulcerative colitis
or Crohn disease).

- Myocardial infarction, unstable angina, cardiac arrhythmias requiring medication,
and/or symptomatic congestive heart failure (New York Heart Association > class II)
within 12 months prior to start of dosing.

- Vasculitis or grade 3/4 gastrointestinal bleeding within 3 months prior to first dose;
vascular disease (eg, aortic aneurysm requiring surgical repair or recent peripheral
arterial thrombosis) within 6 months of first dose.

- Gastrointestinal (GI) perforation and/or fistulae within 6 months prior to start of
dosing.

- Interstitial lung disease or a history of pneumonitis that required oral or
intravenous glucocorticoids to assist with treatment.

- Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic
anticoagulation).

- Chronic systemic corticosteroid therapy or any other immunosuppressive therapies
unless stopped 7 days prior to first dose.

- Any biological therapy or immunotherapy within 3 weeks of start of first dose.

- Major surgery within 4 weeks of first dose.

- Infection requiring IV antimicrobials for management within 7 days of dosing.

- Known human immunodeficiency virus (HIV) infection, hepatitis C infection.

- Active autoimmune disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/08/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/01/2022
Sample size
Target
Accrual to date
Final
3
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Chris OBrien Lifehouse - Camperdown
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Texas
Country [2] 0 0
Austria
State/province [2] 0 0
Salzburg
Country [3] 0 0
Austria
State/province [3] 0 0
Wien

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the
maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04822298
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04822298